Abstract
Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / genetics
-
Antibodies, Monoclonal / immunology*
-
Antibodies, Monoclonal / therapeutic use*
-
Cancer Vaccines / genetics
-
Cancer Vaccines / immunology
-
Cancer Vaccines / metabolism
-
Humans
-
Immunotherapy / methods*
-
Neoplasms / immunology*
-
Neoplasms / therapy*
-
Plants, Genetically Modified / genetics
-
Plants, Genetically Modified / immunology*
-
Protein Engineering / methods
-
Recombinant Proteins / genetics
-
Recombinant Proteins / immunology
-
Recombinant Proteins / therapeutic use
-
Treatment Outcome
-
Tumor Microenvironment
Substances
-
Antibodies, Monoclonal
-
Cancer Vaccines
-
Recombinant Proteins